## STIC-ILL

460,349 YP.NO8/19

From: Sent: Wilson, Michael

Monday, August 18, 2( 03 4:03 PM

To: Subject: STIC-ILL art req. 09/993159

TI Histamine receptors

AU Watanabe, Takehiko; Yanai, Kazuhiko; Fukui, Hiroyuki

SO Tanpakushitsu Kakusan Koso (1997), 42(3), 327-334 CODEN: TAKKAJ; ISSN: 0039-9450

PB Kyoritsu

LA Japanese

TI Histamine H1 receptor-mediate 1 inhibition of potassium-evoked release of 5-hydroxytryptamine from mous 3 forebrains.

AU Son L Ž; Ýanai K; Mobarakeh J I; Kuramasu A; Li Z Y; Sakurai E; Hashimoto SO BEHAVIOURAL BRAIN RESEARCH, (2001 Oct 15) 124 (2) 113-20.

TI IMPROGAN, A HISTAMINE DERIVATIVE, INDUCES ANTINOCICEPTION IN HISTAMINE

RECEPTOR - DEFICIENT MUTANT MICE.

AU Hough, L. B. (1); Nalwalk, J. VV. (1); Mobarakeh, J. I.; Yanai, K.; Stadel,

SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 156.15. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience Orlando, Florida, USA November 02-07, 2002 Society for Neuroscience.

DT Conference

1 1200.

TI Activation of spinal histamine 143 receptors inhibits mechanical nociception

AU Cannon, Keri E.; Nalwalk, Ju ia W.; Stadel, Rebecca; Ge, P.; Lawson, D.;

SO European Journal of Pharmacology (2003), 470(3), 139-147

Michael C. Wilson CM1 12B05 AU 1632 703-305-0120 Lvidoc 8/20

## **Abstract View**

## IMPROGAN, A HISTAMINE DERIVATIVE, INDUCES ANTINOCICEPTION IN HISTAMINE RECEPTOR-DEFICIENT MUTANT MICE

- 1.B. Hough<sup>1</sup>; J.W. Nalwalk<sup>1</sup>; J.J. Mobarakeh<sup>2</sup>; K. Yanai<sup>2</sup>; R. Stadel<sup>1</sup>; J.S. Santiago<sup>2</sup>; M. Hoffman<sup>2</sup>; R. Leurs<sup>4</sup>; H. Homerman<sup>3</sup>; J.N. Carlson<sup>1</sup>;
- 1. Cntr Neuropharmacol Neurosci, Albany Medical College MC-136, Albany, NY, USA
- 2. Dept Pharmacol, Tohoku Univ Schl of Med, Sendai, Japan
- 3. Millennium Pharmaceuticals, Inc., Cambridge, MA, USA
- 4. Leiden/Amsterdam Cnir Drug Res, Vrije Univ, Amsterdam, Netherlands

Improgan is a chemical congener of the histamine H2 receptor antagonist cimetidine which has powerful painrelieving properties when administered directly into the brain. However, improgan has little or no affinity for known histamine receptors, and is also inactive at 50 other sites. To further assess the role of histamine receptors, the effects of improgan were studied in mutant mice deficient in either H1 H2 or H3 receptors. Improgan was given by icv injection (20- 30 ug) and nociceptive responses were measured in the tail flick, hot water tail immersion, or hot plate tests. Improgan induced maximal or near-maximal antinociception lasting from 20 -90 min in all wild-type control mice. When compared with control mice, improgan induced nearly identical responses in H1- and H2 - receptor-deficient mice on the tail flick and hot plate nociceptive tests. In addition, H3 - receptor knockout mice showed equivalent or slightly enhanced improgan antinociception on the tail immersion test when compared with wild-type control mice. Because isoforms of the H3 receptor were recently identified, additional experiments measured improgan s affinity for the rat recombinant H3A, H3B and H3C receptors. Improgan (1 uM) had no effect on specific binding to any of these receptors. Taken together, these results show that improgan induces pain relief by mechanisms which are independent of H1 H2 and H3 receptors. Supported by: DA-03816

## Citation

L.B. Hough, J.W. Nalwalk, J.I. Mobarakeh, K. Yanai, R. Stadel, I.S. Santiago, M. Hoffman, R. Leurs, H. Timmerman, J.N. Carlson. IMPROGAN, A HISTAMINE DERIVATIVE, INDUCES ANTINOCICEPTION IN HISTAMINE RECEPTOR-DEFICIENT MUTANT MICE Program No. 156.15. 2002 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2002. Online.



Site Design and Programming © ScholarOne, Inc., 2002. All Rights Reserved. Patent Pending.

THIS ARTICLE IS FOR INDIVIDUAL USE ONLY AND MAY NOT BE FURTHER REPRODUCED OR STORED ELECTRONICALLY WITHOUT WRITTEN PERMISSION FROM THE COPYRIGHT HOLDER. UNAUTHORIZED REPRODUCTION MAY RESULT IN FINANCIAL AND OTHER PENALTIES.